Dr. Colón brings over 25 years’ experience in biopharma, genomics, diagnostics, health care, drug delivery and industrial biotechnology.
In addition to her role at ProterixBio, Dr. Colón has been a member of Voyager Therapeutics’ board of directors since 2023. She also currently serves as a member of the boards of directors of CareDx, Inc.; the Massachusetts Institute of Technology (MIT) Corporation (MIT’s Board of Trustees); and the Biotechnology Innovation Organization (BIO).
She previously served as President, CEO and Director of InCarda Therapeutics, Inc., where she led the company’s growth from seed stage to late-clinical stage and oversaw strategy, commercial planning and pipeline growth. Prior to InCarda, Dr. Colón served as President and CEO of ProterixBio, and before that as a partner and senior advisor to New Science Ventures LLC.
Prior to New Science Ventures, she was founding President of the Industrial Products Division and Senior Vice President at Intrexon Corporation (NYSE:XON) where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals and was a key contributor to the company’s $100M Series E raise.
Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences (Nasdaq:GILD), where she was responsible for global execution of clinical trials. At Gilead, she also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was VP, Corporate Planning at Affymetrix (acquired by ThermoFisher (NYSE:TMO), where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics.
Earlier in her career, Grace was a consultant at McKinsey & Company, where she served clients in healthcare, high tech, consumer goods and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ.
Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow and recipient of multiple NIH training grants. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.